ZVX-60 / Scorpius Holdings, University of Miami - LARVOL DELTA

[VIRTUAL] Generation of a gp96-Based SARS-CoV-2 Vaccine (ZVX-60) to Induce Long-Lived Memory T-cell Responses Against COVID-19 (VACCINES SUMMIT 2021) - No abstract available

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Heat Biologics Commences Manufacturing Process for ZVX-60 (Streetinsider.com) - "Heat Biologics, Inc....announces it has transferred its gp96-based COVID-19 vaccine cell line ('ZVX-60') to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19....'Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.'"

Commercial • Infectious Disease • Novel Coronavirus Disease

Heat Biologics announces collaboration with Waisman Biomanufacturing to manufacture Covid-19 vaccine (Streetinsider.com) - "Heat Biologics, Inc....announced that it is collaborating with Waisman Biomanufacturing to establish a partnership for the manufacture of Heat's COVID-19 vaccine....Heat Biologics...is collaborating with Waisman to support the manufacturing of its COVID-19 vaccine for expected Phase 1 trials in humans."

Licensing / partnership • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Heat Biologics reports progress on Covid-19 efforts and timeline of anticipated Q2 2020 milestones (Issuer Direct) - "New data suggest that both T-cell (cellular immunity) and antibody (humoral immunity) are required for effective prophylactic protection against COVID-19....Heat's COVID-19 vaccine targets the Spike or S protein, and expresses gp96 and OX40L....*Anticipated* *Q2 2020 milestones include:* Completion of development of a cell-based vaccine expressing gp96-Ig, OX40L-Ig and SARS-CoV-2 protein S; Generation of proof-of-concept data demonstrating vaccine immunogenicity in relevant preclinical models....SARS-CoV-2 protein S specific antibodies in serum; Submission of grant applications to fund and accelerate COVID-19 vaccine development."

Grant • New molecule • Preclinical • Infectious Disease • Novel Coronavirus Disease